Endocrinologic and Metabolic Drugs Advisory Committee

May 19, 2000

A presentation of the data and rationale for the regulatory action regarding the withdrawal from the U. S. market of RezulinJ, (troglitazone, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) for the treatment of type 2 diabetes mellitus.


FDA Presentation: Murray M. Lumpkin, M.D., Deputy Center Director for Review Management .ppt .html